Introduction
Murine models based on implantation of a human bone marrow (huBM) microenvironment [1] [2] [3] [4] [5] [6] recapitulate the in vivo pathophysiology of human multiple myeloma (MM) 7, 8 . They have significant advantages over conventional subcutaneous (s.c.) or disseminated human MM xenograft models for the pre-clinical evaluation of novel agents targeting MM cells and the huBM milieu [9] [10] [11] [12] .
In SCID-hu mice, implantation of patient MM cells in the huBM allows their expansion and the development of measurable manifestations of MM, including bone lesions and production of human paraprotein 8 . Although this model remains the most biologically relevant system for the study of MM pathophysiology, there are limitations in using such in vivo systems for the preclinical investigation of novel agents, particularly in combination therapy, since i) a limited number of MM cells can be harvested from an individual patient, thus limiting the number of mice that can be injected with cells from a single patient; ii) there is significant patient to patient variability in engraftment of disease (2-19 weeks) 8 , therefore limiting the possibility to group animals; and iii) only a fraction of engrafted specimens produce measurable or comparable paraprotein and/or osteolytic lesions. In the past, huBM implanted in SCID-hu mice has been demonstrated to have major effects on the dissemination pattern not only of primary patient MM cells but also on that of MM cell lines, since human tumor cells preferentially migrate and grow in huBM within SCID-hu mice 7 . The majority of available MM cell lines do not require exogenous IL-6 for their proliferation in culture, and when engrafted into SCID mice some of these cell lines form tumors in the absence of huBM [13] [14] [15] [16] . In contrast, primary patient MM cells harvested from huBM are typically IL-6-dependent, and depend on huBM for their ability to engraft in mice 8 .
Here, we describe a novel in vivo SCID-hu model which utilizes the MM cell line INA-6, which is dependent either on exogenous human IL-6 (huIL-6) or human bone marrow stromal cells (BMSCs) for its growth and survival 17 . The huIL-6/BMSC-dependence of INA-6 cells is similar to that of primary MM cells 17 . Consistent with these requirements, INA-6 cells do not produce tumors 
Materials and Methods
Cells and reagents. The establishment and in vitro culture of the huIL-6-dependent MM cell line INA-6 in the presence of 2.5 ng/ml of huIL-6 has been previously described 17 . INA-6 cells were transduced with green fluorescent protein (INA-6 GFP+ ) using a lentiviral vector, as previously described 18 . Human BMSCs from patient BM aspirates after informed consent were isolated as previously described 19 .
propanamine) is a compound that inhibits growth and induce apoptosis of MM cells in vitro 20 . A conjugate of murine anti-CD138 mAb B-B4 and the cytotoxic maytansinoid drug DM1 is a potent anti-MM agent in vitro and in xenograft models in mice 21 .
SCID-hu INA-6 mouse model and in vivo treatments.
Six-to 8-week-old male CB-17 SCID mice (Taconic, NY) were s.c. implanted with human fetal long bone grafts into SCID mice (SCID-hu), as previously described [1] [2] [3] [4] [5] [6] [7] 22 . For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From 6 images were captured with a Sony DSC-P5 digital camera and analyzed using Image-Pro ® Discovery software (MediaCybernetics, Silver Spring, MD).
Histopathological analysis. Human fetal bone implants were fixed in Bouin's solution, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E) for histopathological examination as previously described 7 . Bone implants injected with INA-6 GFP+ cells were frozen, sectioned , fixed in methanol/acetone and serially examined by fluorescence microscopy.
Statistical analysis. Statistical significance of differences was determined using Student's t-test.
Differences were considered significant when p<0.05.
only.
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Results and discussion
The INA-6 cell line 17 requires the presence of either exogenous huIL-6 or BMSCs to promote its in vitro growth, as measured by incorporation of [ 3 H]-thymidine ( Fig. 1A and B) . We (Fig. 1C) . As shown in Fig. 1D , serum shuIL-6R was predictably detected within a narrow range of 33-46 days from cell injection. In all SCID-hu mice, progressive increase of shuIL-6R has been observed following the initial detection (Fig. 1E) . The median survival of SCID-hu mice injected with INA-6 cells was 69±6 days (Fig. 1F) . In contrast, no deaths were observed in SCID mice without bone chip up to 200 days observation following INA-6 cells injection (Fig. 1F) . Importantly, we found increased serum levels of huIL-6 only in SCID-hu mice engrafted with INA-6 cells with higher concentrations of huIL-6 in fetal bone chip aspirates versus tail vein blood (Fig. 1G ). Histological examination of human fetal bone chips following detection of rising levels of shuIL-6R in mouse serum showed a diffuse BM infiltration by MM cells (Fig. 1H ).
We next stably transduced INA-6 cells with a lentiviral vector encoding GFP (INA-6 GFP+ cells) ( Fig. 2A and B-E), and used these cells for external serial real-time fluorescence imaging (RTFI) of SCID-hu mice. Four weeks following the inoculation of INA-6 GFP+ cell in the human bone implants,
RTFI of SCID-hu demonstrated engraftment of fluorescent MM cells in the implanted human bones (Fig. 2F) . This was further confirmed by serial histological analysis of bone implants ( Fig. 2G and   H ).
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We then evaluated the utility of this model in testing conventional and investigational anti-MM agents. As shown in Fig. 2I , treatment of a SCID-hu mouse with dexamethasone (Dex) did not significantly inhibit increase in serum shuIL-6R levels confirming the protective interaction between BMSCs and MM cells as observed in vitro. Treatment with Atipromid, a novel agent with anti-proliferative and apoptotic activity against MM 20 , produced a significant inhibition of shuIL-6R accumulation in MM-bearing mice (Fig. 2L) . Treatment with B-B4-DM1, a novel conjugate of the anti-CD138 mAb with the highly cytotoxic maytansinoid DM1 21 , induced tumor regression, as detected by a decrease in both serum shuIL-6R levels and imaging of MM GFP+ lesions (Fig 2M and   N) . Taken together these results demonstrate that the SCID-hu INA-6 GFP+ model can be used to evaluate anti-MM activity of investigational agents in the huBM milieu.
Although, the SCID-hu mouse model with primary patient MM cells remains a biologically relevant
in vivo system for the study of MM pathophysiology, the inability to produce more than 2-4 mice from each patient sample made statistically significant comparisons of data points very difficult.
The need has been to have a SCID-hu model that can be used to produce a large number of mice with a uniform cell population so that various treatments can be studied and compared in a only.
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